Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis

British Journal of Surgery

Volumn 85, Issue 6, 1998, Pages 818-825

  Wakefield, C H ^a   Barclay, G R ^b   Fearon, K C H ^a,d   Goldie, A S ^a   Ross, J A ^a   Grant, I S ^c   Ramsay, G ^a   Howie, J C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN ANTIBODY; INTERLEUKIN 6;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS;

ACUTE-PHASE REACTION; ANTIBODIES, BACTERIAL; C-REACTIVE PROTEIN; DUODENAL DISEASES; ENDOTOXINS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN; REGRESSION ANALYSIS; STOMACH DISEASES; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031809765     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00710.x     Document Type: Article

References (39)

1. Wittmann DH. World progress in surgery. Intraabdominal infection - introduction. World J Surg 1990; 14: 145-7.
2. Bohnen J, Boulanger R, Meakins JL, McLean AP. Prognosis in generalized peritonitis. Relation to cause and risk factors. Arch Surg 1983; 118: 285-90.
3. Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg 1993; 128: 193-9.
4. Hinsdale JG. Jaffe BM. Re-operation for intra-abdominal sepsis. Indications and results in modern critical care setting. Ann Surg 1984; 199: 31-6.
5. Marshall J, Sweeney D. Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch Surg 1990; 125: 17-23.
6. Dellinger EP, Wertz MJ, Meakins JL, Solomkin JS, Allo MD, Howard RJ et al. Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch Surg 1985; 120: 21-9.
7. Michie HR, Manogue K, Spriggs DR, Revhaug A, O'Dwyer ST, Dinarello CA et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-6.
8. Michie HR, Spriggs DR, Manogue K, Sherman ML, Revhaug A, O'Dwyer ST et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988; 104: 280-6.
9. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
10. Santamaria P, Gehrz R, Bryan MK, Barbosa JJ. Involvement of class II MHC molecules in the LPS-induction of IL-1/TNF secretions by human monocytes: quantitative differences at the polymorphic level. J Immunol 1989; 143: 913-22.
11. 2 shows stable interindividual differences. Scand J Immunol 1988; 27: 705-16.
12. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J et al. Prognostic values of tumour necrosis fuctor/cachectin, interleukin-1, interferon-α, and Interferon-γ in the serum of patients with septic shock. Swiss-Dutch JS Immunoglobulin Study Group. J Infect Dis 1990; 161: 982-7.
13. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-62.
14. Debets JM, Kampmeijer R, van der Linden MPMH, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489-94.
15. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-8.
16. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-36.
17. Fisher CJ Jr, Opal SM, Dhainaut J-F, Stephens S, Zimmerman JL, Nightingale P et al. Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21: 318-27.
18. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk BA, Slotman GJ et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43.
19. Ziegler EJ, Teng NNH, Douglas H, Wunderlich A, Berger HJ, Bolmer SD. Treatment of Pseudomonas bacteremia in neutropenic rabbits with human monoclonal IgM antibody against E. coli lipid A. Clin Res 1987; 35: 619A (Abstract).
20. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-2.
21. Barclay GR. Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: a review. In: Levin J, Alving CR, Munford RS, Redl H, eds. Bacterial Endotoxins: Lipopolysaccharides from Genes to Therapy. New York: J. Wiley, 1995: 263-72.
22. Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA. Detection of tumour necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167: 1344-50.
23. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM et al. Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 1991; 338: 1423-4.
24. Goldie AS, Fearon KCH, Ross JA, Barclay GR, Jackson RE, Grant IS et al. Natural cytokine antagonists and endogenous endotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995; 274: 172-7.
25. Nystrom P-O, Bax R, Dellinger EP, Dominioni L, Knaus WA, Meakins JL et al. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe. World J Surg 1990; 14: 148-58.
26. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989; 17: 389-93.
27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
28. Goris RJA, te Boekhorst TPA, Nuytinck KS, Gimbrere SJ. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985; 120: 1109-15.
29. Tracey KJ, Beutler BA, Lowry SF, Merryweather J, Wolpe S, Milsark IW. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
30. Beutler B, Cerami A. The biology of cachectin/TNF: a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625-55.
31. Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R et al. Endotoxin and cytokine profiles in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock 1991; 33: 84-91.
32. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest 1991; 99: 169-75.
33. Cruickshank AM, Fraser WD, Burns HJG, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79: 161-5.
34. Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg 1992; 79: 757-60.
35. Heinrich PC, Castell CV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36.
36. Rogy MA, Coyle SM, Oldenburg HSA, Rock CS, Barie PS, Van Zee KJ et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994; 178: 132-8.
37. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975-8.
38. Froon AHM, Bemelmans MHA, Greve JW, van der Linden CJ, Buurman WA. Increased plasma concentrations of soluble tumour necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 1994; 22: 803-9.
39. Stüber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-4.